The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy.

Objective: In bleeding patients who are coagulopathic, the clinical response to administration of recombinant factor VIIa (rFVIIa) relates to the changes in prothrombin time (PT).

Design: Retrospective review of all surgical and trauma patients who were coagulopathic and received factor VIIa at the authors' institution over the past 27 months.

Setting: Academic tertiary referral facility and level I trauma center.